Percutaneous Radiofrequency Ablation of Liver Tumors

Percutaneous Radiofrequency Ablation of Liver Tumors

No Results

No Results


Percutaneous radiofrequency (RF) ablation (RFA) is an exciting approach to destroying inoperable primary tumors or metastases in the liver. [1, 2] In the treatment of hepatocellular carcinoma (HCC), fewer than 40% of patients are candidates for surgery, and the rate of recurrence after curative surgery is high. Percutaneous techniques like RFA are, therefore, very important. RFA is widely used for metastatic and small primary tumors. [3] It serves as a bridge for transplant candidates, especially in relation to small primary lesions. [4]

Percutaneous RFA is a minimally invasive, repeatable procedure with few complications. It is performed under radiologic guidance. Randomized controlled trials showed that RFA is superior to ethanol injection in the treatment of small HCCs. [5] RFA results in a higher rate of complete necrosis and requires fewer treatment sessions than percutaneous ethanol injection (PEI). [6, 7, 8]

Long-term survival rates are also better with RFA. A randomized clinical trial showed that RFA yields a significantly better 1-year complete response rate than does PEI. [5] RFA in combination with transcatheter arterial chemoembolization (TACE) is also an effective treatment for inoperable hepatic tumors. [9]  RFA combined with TACE also appears to be safe and effective in the treatment of breast cancer with liver metastasis. [10]

Studies comparing percutaneous RFA and percutaneous microwave coagulation therapy (PMCT) showed better results with RFA in treatment of small tumors. RFA results in better survival rates, fewer complications, and significantly lower local recurrence rates. [11, 12]

In RFA, a needle is inserted into the liver, usually under the guidance of ultrasonography or computed tomography (CT). Once the needle is placed within the tumor, a generator is used to deliver a rapidly alternating current (RF energy). This needle may be bipolar or unipolar; the latter requires grounding pads placed on the patient’s thighs. Heat is generated at the site of the lesion through frictional heat produced by rapid agitation of adjacent cells and produces destruction (liquefactive necrosis) of the tumor.

This technology is used widely in Europe and the United States. Shiina et al noted that by 2007, at least 1500 institutes in Japan had introduced RFA in the treatment of liver tumors. [13]

In the treatment of HCC, the range of indications for percutaneous RFA is becoming wider than that of surgery and intra-arterial therapies, and it includes the following main categories [5, 1] :

Contraindications for percutaneous RFA of liver tumors include the following:

One randomized controlled trial showed that the 2-year recurrence rate of HCC was significantly lower with RFA than with percutaneous ethanol injection (PEI). When compared with surgical resection, the recurrence rate is higher after RFA, with less time to recurrence. [33]  Recurrence is more common with the percutaneous approach as compared with open or laparoscopic RFA. The rate of recurrence is also higher with lesions larger than 3 cm. [34]

In a study by Toshimori et al, the local recurrence rates after percutaneous RFA for HCC were 2.2% at 1 year, 7.4% at 3 years, and 9.5% at 5 years. [35] Factors that predisposed to local recurrence included large tumor size (>2 cm), tumor location adjacent to the major portal branch or hepatic vein), and a small (<3 mm) ablated margin.

Shady et al assessed factors affecting outcome in patients with colorectal cancer liver metastases who were treated with percutaneous RFA. [36] On multivariate analysis, factors predictive of shorter local tumor progression-free survival were a tumor size exceeding 3 cm and a margin size of 5 mm or less; factors predictive of shorter overall survival were a tumor size exceeding 3 cm and the the presence of more than one site of extra-hepatic disease.

Yamao et al compared the survival impacts of RFA (n = 33) and hepatic resection (n = 71) as initial treatment of HCC in 104 patients with liver damage B as defined by the Liver Cancer Study Group of Japan. [37] Whereas overall survival (OS) tended to be better in the RFA group, disease-free survival (DFS) did not differ significantly between groups. Subgroup analyses found OS with RFA to be significantly better in patients with aspartate aminotransferase above 35 IU/L, serum albumin below 3.5 g/dL, and 99mTc-galactosyl human serum albumin below 0.85.

Howard JH, Tzeng CW, Smith JK, et al. Radiofrequency ablation for unresectable tumors of the liver. Am Surg. 2008 Jul. 74(7):594-600; discussion 600-1. [Medline].

Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr. Liver Ablation: Best Practice. Radiol Clin North Am. 2015 Sep. 53 (5):933-71. [Medline].

Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005 Mar. 234(3):961-7. [Medline].

Buell JF, Thomas MT, Rudich S, et al. Experience with more than 500 minimally invasive hepatic procedures. Ann Surg. 2008 Sep. 248(3):475-86. [Medline].

Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol. 2008. 43 (6):727-35. [Medline].

Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999 Mar. 210(3):655-61. [Medline].

Ansari D, Andersson R. Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors. World J Gastroenterol. 2012 Mar 14. 18(10):1003-8. [Medline]. [Full Text].

Cha DI, Lee MW, Rhim H, Choi D, Kim YS, Lim HK. Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations. Korean J Radiol. 2013 Mar-Apr. 14(2):240-7. [Medline]. [Full Text].

Yamagiwa K, Shiraki K, Yamakado K, et al. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. J Gastroenterol Hepatol. 2008 Mar. 23(3):482-90. [Medline].

Wang H, Liu B, Long H, Zhang F, Wang S, Li F. Clinical study of radiofrequency ablation combined with TACE in the treatment of breast cancer with liver metastasis. Oncol Lett. 2017 Sep. 14 (3):2699-2702. [Medline].

Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, et al. Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. J Gastroenterol Hepatol. 2009 Feb. 24 (2):223-7. [Medline].

Ohmoto K, Yoshioka N, Tomiyama Y, et al. Radiofrequency ablation versus percutaneous microwave coagulation therapy for small hepatocellular carcinomas: a retrospective comparative study. Hepatogastroenterology. 2007 Jun. 54(76):985-9. [Medline].

Shiina S. Japanese experience in ablation therapies for hepatocellular carcinoma. Hepatol Res. 2007 Sep. 37 Suppl 2:S223-9. [Medline].

Lencioni R, Crocetti L. A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma. Clin Liver Dis. 2005 May. 9(2):301-14, viii. [Medline].

Crocetti L, Lencioni R. Thermal ablation of hepatocellular carcinoma. Cancer Imaging. 2008 Feb 27. 8:19-26. [Medline].

Salmi A, Turrini R, Lanzani G, et al. Long-term effectiveness of radiofrequency ablation for hepatocellular carcinoma of 3.5 cm or less. Hepatogastroenterology. 2008 Jan-Feb. 55(81):191-6. [Medline].

Kim GA, Shim JH, Kim MJ, Kim SY, Won HJ, Shin YM, et al. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. Br J Surg. 2016 Jan. 103 (1):126-35. [Medline].

Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol. 2005 May. 31(4):331-47. [Medline].

Smith S, Gillams A. Imaging appearances following thermal ablation. Clin Radiol. 2008 Jan. 63(1):1-11. [Medline].

Grundmann RT, Hermanek P, Merkel S, et al. [Diagnosis and treatment of colorectal liver metastases – workflow]. Zentralbl Chir. 2008 Jun. 133(3):267-84. [Medline].

Lawes D, Chopada A, Gillams A, Lees W, Taylor I. Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastasis from breast cancer. Ann R Coll Surg Engl. 2006 Nov. 88(7):639-42. [Medline].

Wertenbroek MW, Links TP, Prins TR, Plukker JT, van der Jagt EJ, de Jong KP. Radiofrequency ablation of hepatic metastases from thyroid carcinoma. Thyroid. 2008 Oct. 18(10):1105-10. [Medline].

Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging. 2005 Jul-Aug. 30(4):435-41. [Medline].

Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol. 2000 Sep. 7(8):593-600. [Medline].

Chen S, Peng Z, Xiao H, Lin M, Chen Z, Jiang C, et al. Combined Radiofrequency Ablation and Ethanol Injection Versus Repeat Hepatectomy for Elderly Patients with Recurrent Hepatocellular Carcinoma after Initial Hepatic Surgery. Int J Hyperthermia. 2017 Oct 4. 1-34. [Medline].

van Duijnhoven FH, Jansen MC, Junggeburt JM, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol. 2006 May. 13(5):651-8. [Medline].

Seror O, Haddar D, N’Kontchou G, et al. Radiofrequency ablation for the treatment of liver tumors in the caudate lobe. J Vasc Interv Radiol. 2005 Jul. 16(7):981-90. [Medline].

Hatanaka T, Kakizaki S, Yuhei S, Takeuchi S, Shimada Y, Takizawa D, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma located in the caudate lobe of the liver. Acta Gastroenterol Belg. 2015 Jul-Sep. 78 (3):267-73. [Medline].

Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncologist. 2001. 6 (1):24-33. [Medline].

Huang GT, Liang JD, Sheu JC. Current role of local ablative treatments for hepatocellular carcinoma. J Formos Med Assoc. 2004 Jun. 103(6):403-10. [Medline].

Lencioni R, Cioni D, Crocetti L, Bartolozzi C. Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl. 2004 Feb. 10(2 Suppl 1):S91-7. [Medline].

Lencioni R, Della Pina C, Bartolozzi C. Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma. Abdom Imaging. 2005 Jul-Aug. 30(4):401-8. [Medline].

Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg. 2006 Feb. 141(2):181-90. [Medline].

Penka I, Kaplan Z, Sefr R, Sirotek L, Eber Z, Ondrak M. Use of radiofrequency ablation in the treatment of malignant liver lesions. Hepatogastroenterology. 2008 Mar-Apr. 55(82-83):562-7. [Medline].

Toshimori J, Nouso K, Nakamura S, Wada N, Morimoto Y, Takeuchi Y, et al. Local Recurrence and Complications after Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma: A Retrospective Cohort Study Focused on Tumor Location. Acta Med Okayama. 2015 Aug. 69 (4):219-26. [Medline].

Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, et al. Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes–A 10-year Experience at a Single Center. Radiology. 2016 Feb. 278 (2):601-11. [Medline].

Yamao T, Imai K, Yamashita YI, Kaida T, Nakagawa S, Mima K, et al. Surgical treatment strategy for hepatocellular carcinoma in patients with impaired liver function: hepatic resection or radiofrequency ablation?. HPB (Oxford). 2017 Oct 5. [Medline].

Weissleder R, Wittenberg J, Harisinghani MG, Chen JW. Gastrointestinal imaging. Primer of Diagnostic Imaging. 5th ed. St Louis: Elsevier Mosby; 2011. 150-61.

Mulier S, Ni Y, Miao Y, et al. Size and geometry of hepatic radiofrequency lesions. Eur J Surg Oncol. 2003 Dec. 29(10):867-78. [Medline].

Hansler J, Frieser M, Tietz V, et al. Percutaneous ultrasound-guided radiofrequency ablation (RFA) using saline-perfused (wet) needle electrodes for the treatment of hepatocellular carcinoma–long term experience. Ultraschall Med. 2007 Dec. 28(6):604-11. [Medline].

Panpikoon T, Treesit T, Thapaneeyakorn J, Wedsart B, Inman T. Efficacy of percutaneous radiofrequency ablation of hepatic malignant tumors using a perfused-cooled electrode. J Med Assoc Thai. 2013 Jan. 96(1):77-82. [Medline].

Curley SA. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol. 2003 May. 10(4):338-47. [Medline].

Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003 Feb. 226(2):441-51. [Medline].

Carrafiello G, Lagana D, Ianniello A, et al. Post-radiofrequency ablation syndrome after percutaneous radiofrequency of abdominal tumours: one centre experience and review of published works. Australas Radiol. 2007 Dec. 51(6):550-4. [Medline].

Giorgio A, Tarantino L, de Stefano G, Coppola C, Ferraioli G. Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. AJR Am J Roentgenol. 2005 Jan. 184(1):207-11. [Medline].

Giovannini M, Moutardier V, Danisi C, Bories E, Pesenti C, Delpero JR. Treatment of hepatocellular carcinoma using percutaneous radiofrequency thermoablation: results and outcomes in 56 patients. J Gastrointest Surg. 2003 Sep-Oct. 7(6):791-6. [Medline].

Kim SK, Lim HK, Kim YH, et al. Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings. Radiographics. 2003 Jan-Feb. 23(1):107-21. [Medline].

Lim HK, Choi D, Lee WJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology. 2001 Nov. 221(2):447-54. [Medline].

Tsuda M, Majima K, Yamada T, Saitou H, Ishibashi T, Takahashi S. Hepatocellular carcinoma after radiofrequency ablation therapy: dynamic CT evaluation of treatment. Clin Imaging. 2001 Nov-Dec. 25(6):409-15. [Medline].

Nghiem HV, Francis IR, Fontana R, et al. Computed tomography appearances of hypervascular hepatic tumors after percutaneous radiofrequency ablation therapy. Curr Probl Diagn Radiol. 2002 May-Jun. 31(3):105-11. [Medline].

Filippone A, Iezzi R, Di Fabio F, Cianci R, Grassedonio E, Storto ML. Multidetector-row computed tomography of focal liver lesions treated by radiofrequency ablation: spectrum of findings at long-term follow-up. J Comput Assist Tomogr. 2007 Jan-Feb. 31(1):42-52. [Medline].

Catalano O, Lobianco R, Esposito M, Siani A. Hepatocellular carcinoma recurrence after percutaneous ablation therapy: helical CT patterns. Abdom Imaging. 2001 Jul-Aug. 26(4):375-83. [Medline].

Chen MH, Wu W, Yang W, et al. The use of contrast-enhanced ultrasonography in the selection of patients with hepatocellular carcinoma for radio frequency ablation therapy. J Ultrasound Med. 2007 Aug. 26(8):1055-63. [Medline].

Wu J, Yang W, Yin S, Wu J, Wu W, Yan K, et al. Role of contrast-enhanced ultrasonography in percutaneous radiofrequency ablation of liver metastases and efficacy evaluation. Chin J Cancer Res. 2013 Apr. 25(2):143-54. [Medline]. [Full Text].

Nicolau C, Vilana R, Bianchi L, Bru C. Early-stage hepatocellular carcinoma: the high accuracy of real-time contrast-enhanced ultrasonography in the assessment of response to percutaneous treatment. Eur Radiol. 2007 Dec. 17 Suppl 6:F80-8. [Medline].

Meloni MF, Livraghi T, Filice C, Lazzaroni S, Calliada F, Perretti L. Radiofrequency ablation of liver tumors: the role of microbubble ultrasound contrast agents. Ultrasound Q. 2006 Mar. 22(1):41-7. [Medline].

Brünn K, Beyer L, Haimerl M, Pregler B, Stroszczynski C, Jung EM, et al. Comparison of computed tomography (CT) and contrast-enhanced ultrasound (CEUS) for the quantitative evaluation of an ablation defect following radiofrequency ablation of malignant liver lesions. Clin Hemorheol Microcirc. 2017 Sep 4. [Medline].

Wen YL, Kudo M, Zheng RQ, et al. Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol. 2003 Jul. 181(1):57-63. [Medline].

Bartolozzi C, Lencioni R, Caramella D, Mazzeo S, Ciancia EM. Treatment of hepatocellular carcinoma with percutaneous ethanol injection: evaluation with contrast-enhanced MR imaging. AJR Am J Roentgenol. 1994 Apr. 162(4):827-31. [Medline].

Sironi S, Livraghi T, Meloni F, De Cobelli F, Ferrero C, Del Maschio A. Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up. AJR Am J Roentgenol. 1999 Nov. 173(5):1225-9. [Medline].

Dromain C, de Baere T, Elias D, et al. Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology. 2002 Apr. 223(1):255-62. [Medline].

Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol. 2006 Sep. 9(3):125-32. [Medline].

Travaini LL, Trifiro G, Ravasi L, et al. Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging. 2008 Jul. 35(7):1316-22. [Medline].

Kuehl H, Antoch G, Stergar H, et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol. 2008 Aug. 67(2):362-71. [Medline].

Donckier V, Van Laethem JL, Goldman S, et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol. 2003 Dec. 84(4):215-23. [Medline].

Badar Bin Bilal Shafi, MBBS, MRCP, FRCR, CCT, EBIR Consultant Interventional Radiologist, South Mersey Vascular Centre and Countess of Chester Hospital, UK

Badar Bin Bilal Shafi, MBBS, MRCP, FRCR, CCT, EBIR is a member of the following medical societies: Radiological Society of North America, Royal College of Physicians, Royal College of Radiologists, Society of Interventional Radiology, Cardiovascular and Interventional Radiological Society of Europe, British Society of Interventional Radiology

Disclosure: Nothing to disclose.

R H Bilal, MBBS, MRCS Specialist Registrar in Cardiothoracic Surgery, North West Cardiothoracic Rotation, UK

R H Bilal, MBBS, MRCS is a member of the following medical societies: British Medical Association

Disclosure: Nothing to disclose.

Jonathan C Evans, MBChB, MRCP, DMRD, FRCR Radiologist, Interventional Radiology and GI Imaging, Royal Liverpool University Hospital, UK

Jonathan C Evans, MBChB, MRCP, DMRD, FRCR is a member of the following medical societies: Royal College of Radiologists

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Kurt E Roberts, MD Assistant Professor, Section of Surgical Gastroenterology, Department of Surgery, Director, Surgical Endoscopy, Associate Director, Surgical Skills and Simulation Center and Surgical Clerkship, Yale University School of Medicine

Kurt E Roberts, MD is a member of the following medical societies: American College of Surgeons, Society of American Gastrointestinal and Endoscopic Surgeons, Society of Laparoendoscopic Surgeons

Disclosure: Nothing to disclose.

Percutaneous Radiofrequency Ablation of Liver Tumors

Research & References of Percutaneous Radiofrequency Ablation of Liver Tumors|A&C Accounting And Tax Services